Biotech Amarin (NASDAQ: AMRN ) has slide more than 20% since launching its hypertriglyceridemia drug Vascepa in January. The company's market value has dropped following months of indecision regarding the drug's exclusivity status and question marks over the drug's launch. As the stock continues to be hotly debated, there are two catalysts in particular that investors should watch. Health-care analyst Max Macaluso discusses each in the following video.
Can Amarin beat the odds?
Small biotech companies usually crash and burn when it comes to launching drugs -- but can Amarin prove the doubters wrong with its new lipid-lowering drug? In our new premium research report, The Motley Fool's top biotech analyst offers an in-depth look at this drugmaker's upcoming opportunities, along with reasons to buy and sell this stock today. To find out more, simply click here now to claim your copy.
Editor's Note: At 1:00, the speaker meant to say eight months.
No comments:
Post a Comment